Back to Search
Start Over
The DESolve novolimus bioresorbable Scaffold: from bench to bedside.
- Source :
-
Journal of thoracic disease [J Thorac Dis] 2017 Aug; Vol. 9 (Suppl 9), pp. S950-S958. - Publication Year :
- 2017
-
Abstract
- The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and in vitro bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3- to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment. Overexpansion with DESolve is safe since a high capability resistance to fracture has been demonstrated with this scaffold. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding the DESolve.<br />Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 2072-1439
- Volume :
- 9
- Issue :
- Suppl 9
- Database :
- MEDLINE
- Journal :
- Journal of thoracic disease
- Publication Type :
- Academic Journal
- Accession number :
- 28894601
- Full Text :
- https://doi.org/10.21037/jtd.2017.07.25